| Literature DB >> 30995194 |
Misako Dai1, Gojiro Nakagami2,3, Junko Sugama4, Noriko Kobayashi5, Emiko Kimura6, Yoko Arai7, Aya Sato8, Gregoire Mercier9, Christine Moffatt10, Susie Murray11, Hiromi Sanada2,3.
Abstract
Background: This was a part of LIMPRINT (Lymphoedema IMpact and PRevalence-INTernational), an international study aimed at capturing the size and impact of lymphedema and chronic edema in different countries and health services across the world. The purpose of this study was to clarify the prevalence and the impact of chronic edema in Japan. Methods andEntities:
Keywords: chronic edema; impact; lymphedema; lymphoedema; prevalence
Mesh:
Year: 2019 PMID: 30995194 PMCID: PMC6639102 DOI: 10.1089/lrb.2018.0080
Source DB: PubMed Journal: Lymphat Res Biol ISSN: 1539-6851 Impact factor: 2.589
Characteristics of Participants in Each Facility
| Age (years) | 72 (68–74) | 68 (59–74) | 59.5 (50–72) | 85 (80–90) |
| Sex | ||||
| Male | 0 (0.0) | 1 (5.0) | 4 (40.0) | 7 (23.3) |
| Female | 51 (100.0) | 19 (95.0) | 6 (60.0) | 23 (76.7) |
| BMI (kg/m2) | ||||
| <18.5 | 2 (3.9) | 0 (0.0) | 3 (30.0) | 6 (20.0) |
| 18.5 to <25.0 | 30 (58.8) | 12 (60.0) | 5 (50.0) | 23 (76.7) |
| 25.0 to <30.0 | 14 (27.5) | 8 (40.0) | 2 (20.0) | 1 (3.3) |
| ≥30.0 | 5 (9.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Upper limb mobility | ||||
| Full range of movement | 50 (98.0) | 17 (85.0) | 9 (90.0) | 14 (46.7) |
| Limited range of movement | 1 (2.0) | 1 (5.0) | 0 (0.0) | 1 (3.3) |
| No function | 0 (0.0) | 2 (10.0) | 1 (10.0) | 0 (0.0) |
| Lower limb mobility | ||||
| Walks unaided | 50 (98.0) | 20 (100.0) | 5 (50.0) | 6 (20.0) |
| Walks with aid | 1 (2.0) | 0 (0.0) | 1 (10.0) | 13 (43.3) |
| Chair bound | 0 (0.0) | 0 (0.0) | 3 (30.0) | 8 (26.7) |
| Bed bound | 0 (0.0) | 0 (0.0) | 1 (10.0) | 3 (10.0) |
| Immobility | 0 (0.0) | 0 (0.0) | 2 (20.0) | 29 (96.7) |
| Comorbidity | ||||
| Diabetes mellitus | 4 (7.8) | 3 (15.0) | 2 (20.0) | 7 (23.3) |
| Heart failure and/or ischemic heart disease | 0 (0.0) | 1 (5.0) | 1 (10.0) | 3 (10.0) |
| Neurological disorder | 2 (3.9) | 1 (5.0) | 0 (0.0) | 1 (3.3) |
| Peripheral arterial disease | 0 (0.0) | 3 (15.0) | 0 (0.0) | 0 (0.0) |
N (%), median (interquartile range).
BMI, body mass index.
Condition and Management of Chronic Edema and Lymphedema in Each Facility
| Classification of edema | ||||
| Primary lymphedema | 2 (3.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Secondary lymphedema | 49 (96.1) | 18 (90.0) | 4 (40.0) | 0 (0.0) |
| Unknown | 0 (0.0) | 2 (10.0) | 6 (60.0) | 30 (100.0) |
| Secondary swelling due to cancer | ||||
| Breast cancer | 13 (25.5) | 10 (50.0) | 3 (30.0) | — |
| Endometrial/cervical cancer | 24 (47.1) | 8 (40.0) | 0 (0.0) | — |
| Gastric/liver/colorectal cancer | 2 (3.9) | 0 (0.0) | 1 (10.0) | — |
| Others | 12 (23.5) | 2 (10.0) | 6 (60.0) | — |
| Treatment of lymphatic obstruction | 49 (96.1) | 20 (100.0) | 4 (40.0) | 0 (0.0) |
| Duration of edema | ||||
| 3–6 Months | 1 (2.0) | 1 (5.0) | 7 (70.0) | 4 (13.3) |
| 6 Months to 1 year | 1 (2.0) | 3 (15.0) | 2 (20.0) | 8 (26.7) |
| 1–2 Years | 2 (3.9) | 2 (10.0) | 0 (0.0) | 3 (10.0) |
| 2–5 Years | 9 (17.6) | 5 (25.0) | 0 (0.0) | 4 (13.3) |
| 5–10 Years | 23 (45.1) | 5 (25.0) | 1 (10.0) | 4 (13.3) |
| >10 Years | 15 (29.4) | 4 (20.0) | 0 (0.0) | 7 (23.3) |
| Cellulitis | 25 (49.0) | 3 (15.0) | 3 (30.0) | 4 (13.3) |
| Infection | 9 (17.6) | 2 (10.0) | 1 (10.0) | 4 (13.3) |
| Hospitalization due to cellulitis | 0 (0.0) | 1 (5.0) | 1 (10.0) | 1 (3.3) |
| Infection, number of times | ||||
| 0 | 42 (82.4) | 18 (90.0) | 9 (90.0) | 26 (86.7) |
| 1 | 5 (9.8) | 2 (10.0) | 0 (0.0) | 3 (10.0) |
| 2 | 2 (3.9) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
| 3 | 2 (3.9) | 0 (0.0) | 0 (0.0) | 1 (3.3) |
| Skin care advice | 48 (94.1) | 19 (95.0) | 3 (30.0) | 0 (0.0) |
| Wound dressing use | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.3) |
| Antibiotic use | 13 (25.5) | 0 (0.0) | 0 (0.0) | 1 (3.3) |
| Massage | 51 (100.0) | 16 (80.0) | 1 (10.0) | 11 (36.7) |
| Physiotherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (43.3) |
| Compression garment | 49 (96.1) | 20 (100.0) | 4 (40.0) | 0 (0.0) |
| Multi-layer bandage | 34 (66.7) | 15 (75.0) | 1 (10.0) | 0 (0.0) |
| Pneumatic compression pumps | 0 (0.0) | 0 (0.0) | 1 (10.0) | 1 (3.3) |
| Debulking lymphedema (lymphatic surgery) | 7 (13.7) | 1 (5.0) | 0 (0.0) | 0 (0.0) |
| Main categories of treatment within Complex Decongestive Therapy | ||||
| Exercise advice | 40 (80.0) | 17 (85.0) | 1 (0.0) | 0 (0.0) |
| Cellulitis advice | 49 (98.0) | 19 (95.0) | 1 (0.0) | 0 (0.0) |
| Psychological support | 43 (86.0) | 10 (50.0) | 0 (0.0) | 0 (0.0) |
| Subjective control of chronic edema: in your opinion, is the swelling well controlled? | 23 (46.0) | 10 (50.0) | 5 (50.0) | 13 (43.3) |
N (%).
Anatomical Locations of Chronic Edema for Both Sides of the Whole Body
| Head, neck, and face | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Upper limbs | ||||
| Fingers | 10 (9.8) | 8 (20.0) | 1 (5.0) | 1 (1.7) |
| Hand | 10 (9.8) | 8 (20.0) | 2 (10.0) | 2 (3.3) |
| Lower arm | 13 (12.7) | 10 (25.0) | 3 (15.0) | 3 (5.0) |
| Upper arm | 12 (11.8) | 11 (27.5) | 1 (5.0) | 2 (3.3) |
| Shoulder | 4 (3.9) | 8 (20.0) | 0 (0.0) | 1 (1.7) |
| Lower limbs | ||||
| Toes | 31 (30.4) | 4 (10.0) | 5 (25.0) | 11 (18.3) |
| Foot | 40 (39.2) | 9 (22.5) | 13 (65.0) | 28 (46.7) |
| Lower leg | 41 (40.2) | 12 (30.0) | 14 (70.0) | 23 (38.3) |
| Upper leg | 43 (42.2) | 11 (27.5) | 10 (50.0) | 3 (5.0) |
| Trunk | ||||
| Buttock | 21 (20.6) | 4 (0.0) | 4 (20.0) | 0 (0.0) |
| Abdomen | 20 (19.6) | 0 (0.0) | 4 (20.0) | 0 (0.0) |
| Upper chest-breast | 2 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Genital area (vulva, scrotum, and penis) | 2 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
N (%), numbers show both sides of each body part. Physician: gynecologist.
Lymphedema Status of Outpatients in Acute Care Hospitals
| Stemmers sign | ||||
| Present | 2 (15.4) | 20 (52.6) | 7 (70.0) | 5 (50.0) |
| Absent | 11 (84.6) | 18 (47.4) | 3 (30.0) | 5 (50.0) |
| ISL classification | ||||
| ISL stage I | 2 (15.4) | 1 (2.6) | 0 (0.0) | 0 (0.0) |
| ISL stage II | 9 (69.2) | 11 (28.9) | 7 (70.0) | 4 (40.0) |
| ISL stage late II | 2 (15.4) | 24 (63.2) | 3 (30.0) | 4 (40.0) |
| ISL stage III | 0 (0.0) | 2 (5.3) | 0 (0.0) | 1 (10.0) |
N (%).
ISL, International Society of Lymphology.
Disease-Specific Quality-of-Life Status in Acute Care Hospitals
| WHODAS 2.0 | 0.0 (0.0–10.4) | 2.1 (0.0–3.1) | 58.3 (37.5–72.9) |
| EQ-5D | |||
| Utility score | 1.000 (0.796–1.000) | 0.796 (0.796–1.000) | 0.516 (0.312–1.000) |
| Perceived health status | 88.0 (88.0–100.0) | 100 (99.6–100.0) | 71.7 (60.0–100.0) |
| LYMQOL: upper limb | |||
| Function | 1.2 (1.0–2.2) | 1.45 (1.2–2.0) | 2.0 |
| Appearance | 1.8 (1.0–2.6) | 1.7 (1.4–2.2) | 1.4 |
| Symptom | 2.3 (1.7–2.7) | 1.9 (1.5–2.3) | 3.0 |
| Mood | 1.0 (1.0–2.0) | 1.9 (1.0–2.5) | 2.8 |
| Overall | 8.0 (7.0–9.0) | 7.25 (6.0–8.0) | 4.0 |
| LYMQOL: lower limb | |||
| Function | 1.6 (1.1–2.3) | 1.5 (1.1–2.0) | 2.8 (2.5–2.8) |
| Appearance | 2.3 (1.2–2.8) | 2.2 (1.3–2.8) | 2.2 (2.0–2.3) |
| Symptom | 2.0 (1.3–2.7) | 1.9 (1.7–2.2) | — |
| Mood | 2.0 (1.7–2.3) | 1.3 (1.0–2.0) | 2.8 (2.5–3.0) |
| Overall | 8.0 (6.0–8.0) | 7.5 (6.0–8.0) | 5.0 (4.0–6.0) |
Median (interquartile range).